Home › Alzheimer's Disease › NCT06810960

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

A 6-Year Postmarketing Safety and Clinical Outcome Study of LEQEMBI® in the Treatment of Alzheimer's Disease Using Real-World Data From South Korean Patients Enrolled Into the South Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) Registry

Who can join

Ages 19 and older · All sexes

Inclusion Criteria:

* Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
* The clinical decision to treat with LEQEMBI has already been made
* Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

Exclusion Criteria:

* Currently participating in an interventional clinical study

About the study

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

What is being tested

• No Intervention (other)

Sponsor: Eisai Korea Inc. · Participants: 3,000 · Started: Feb 24, 2025

Contact the study team

• Eisai Korea Inc. Medical department Serena SoYoun Kwon · Phone: +82-2-3451-5533

Official record on ClinicalTrials.gov — NCT06810960

Locations in the U.S.

Conditions

• Alzheimer's Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.